VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update [Yahoo! Finance]
VolitionRX Limited (VNRX)
NASDAQ:AMEX Investor Relations:
ir.volitionrx.com
Company Research
Source: Yahoo! Finance
HENDERSON, Nevada March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and full fiscal year ended December 31 , 2024. Volition management will host a conference call today, March 31 at 4:30 p.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Highlights Sold approximately 120,000 Nu.Q® Vet Cancer Tests in 2024. Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in over 20 countries worldwide. A range of independent studies completed, demonstrating the value of our Nu.Q® platform in both sepsis and oncology. Advancing several active commercial discussions with significant players in the human diagnostic and liquid biopsy space for sepsis and oncology, constituting multibillion dollar markets. Strengthened the Board of Directors in the appointment of experienced ch
Show less
Read more
Impact Snapshot
Event Time:
VNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNRX alerts
High impacting VolitionRX Limited news events
Weekly update
A roundup of the hottest topics
VNRX
News
- VolitionRx (NYSE:VNRX) had its price target lowered by analysts at D. Boral Capital from $5.00 to $3.00. They now have a "buy" rating on the stock.MarketBeat
- Volition Issues Business Review 2025PR Newswire
- Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) EnrichmentPR Newswire
- Volition Announces Two Abstracts were Presented at the North America Conference on Lung CancerPR Newswire
- VolitionRx (NYSE:VNRX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
VNRX
Earnings
- 11/13/25 - Miss
VNRX
Sec Filings
- 12/11/25 - Form 8-K
- 11/17/25 - Form 4
- 11/14/25 - Form SCHEDULE
- VNRX's page on the SEC website